Until recently, there have been no practical technologies that could actively reduce cytokine storm effectively – the holy grail of the industry for the past three decades. Cytosorbents has the approved technology that reduce cytokines broadly in human patients with sepsis.
The wearable artificial kidney (WAK) has been the holy grail for the past five decades. Renal Solutions has an approved technology that can regenerates used dialysate into fresh, highly pure dialysate using 6 liters of water. One course of hemodialysis normally uses about 100+ liters of water.
I think a partnership between the Fresenius and Cytosorbents is more likely for now. Fresenius is not a company that sits still and they are very interested in ground breaking products. See below.
A strong innovation culture - steeped in tradition
Fresenius Medical Care's wide range of products and therapies are the result of long-term research and development activities. This R&D has often been carried out at a time when its full potential could not be foreseen. The results have included: methods for producing sterile and pyrogen-free dialysate and online haemodiafiltration, and, procedures to actively control the thermal energy balance and blood volume of dialysis patients during treatment.
Today these are standard methods in the treatment of chronic kidney disease. As a result of Fresenius Medical Care's innovation culture, the company was able to participate and leverage this development early on.
This innovative culture is one of the reasons why we consistently deliver groundbreaking products and treatments for those suffering chronic kidney failure. We capitalise on the size and strength of our company, and fully utilise all of the technological, medical, and economic possibilities available to us, in order to improve the length and quality of life of dialysis patients.
Market Data 
Markets 
AI
